FOR ADULTS WITH ACTIVE PSORIATIC ARTHRITIS (PsA)
*year-to-date TREMFYA® active PsA market share vs IL-23 inhibitors as of July 2023.
Give your patients the opportunity to emerge with:
Rapid joint improvement proven to last at 2 years*†‡
Rapid joint improvement at Week 24 (primary endpoint) with response as early as Week 4 and continued improvement at 2 years* (OLE NRI post hoc analysis)1-7
Extensive relief: More than just lasting skin clearance at 2 years†
Improvement in IGA 0/1 at Weeks 24 and 100, with additional data including PASI 90, enthesitis, dactylitis, HAQ-DI, and MDA1-6
Proven safety profile in psoriatic disease§
Proven safety across 4 pivotal clinical trials in moderate to severe plaque psoriasis and active PsA1
References: 1. TREMFYA® (guselkumab) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. 2. Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naïve patients with active psoriatic arthritis (DISCOVER 2): a double-blind, randomized, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1126-1136. 3. Deodhar A, Helliwell PS, Boehncke W-H, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naïve or had previously received TNFα inhibitor treatment (DISCOVER 1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1115-1125. 4. McInnes IB, Rahman P, Gottlieb AB, et al. Efficacy and safety of guselkumab, an interleukin-23p19-specific monoclonal antibody, through one year in biologic-naïve patients with psoriatic arthritis. Arthritis Rheumatol. 2021;73(4):604-616. 5. McInnes IB, Rahman P, Gottlieb AB, et al. Efficacy and safety of guselkumab, a monoclonal antibody specific to the p-19 subunit of interleukin-23, through 2 years: results from a phase 3, randomized, double-blind, placebo-controlled study conducted in biologic-naïve patients with active psoriatic arthritis. Poster presented at: Innovations in Dermatology 2021; Virtual; March 16-20, 2021. 6. Data on file. Janssen Biotech, Inc. 7. Data provided by Managed Markets Insight & Technology, LLC™, a trademark of MMIT, as of October 2023.